

# A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

NCT07016750

---

Status	RECRUITING
Phase	Phase 3
Sponsor	Krystal Biotech, Inc.
Enrollment	16 participants

## Key Eligibility Criteria

---

### Inclusion (4)

- The subject and/or their parent/legal guardian must provide informed consent/assent and must be able to and willing to follow study procedures and instructions.
- Age 6 months or older at time of informed consent/assent.
- Confirmed diagnosis of DEB with a mutation in the COL7A1 gene.
- Meets minimum corneal abrasion symptom frequency in the NHS study.

### Exclusion (6)

- Initiation of any new treatment regimen or change in treatment for ocular disease during the run-in period except for preservative free topical antibiotics or artificial tears/lubricants associated with standard of care treatment of corneal abrasions.
- Treatment with an investigational agent or off-label ophthalmic use of an approved product during the run-in period or planned use during the study (Exceptions may be approved by the medical monitor on a case-by-case basis).
- Any condition that, in the opinion of the Investigator, would impact the completion of all study-related assessments, interfere with the administration of study drug, and/or poses an additional risk to the subject.
- Women who are pregnant or nursing.
- Subject who is unwilling to comply with contraception requirements per protocol.

... and 1 more (see full listing online)

## Locations (5 total)

---

Mission Dermatology Center, Rancho Santa Margarita, California, United States

Skin Research Institute, Coral Gables, Florida, United States

UMass Memorial Medical Center, Worcester, Massachusetts, United States

... and 2 more locations